Estimated within-participant changes from cycle 1, day 1 administration of pembrolizumab of (A) unspliced HIV RNA, (B) HIV DNA, (C) the ratio of unspliced HIV RNA:HIV DNA, and (D) plasma HIV RNA are shown. The y axis scale is log-transformed. Dots represent point estimates from regression analyses, and error bars indicate 95% confidence intervals; dashed line indicates no change from baseline; and exclusion of dashed line from confidence interval indicates P < 0.05 by Wald test of regression coefficient.